InsidersTradesSigma
Follow the Amneal Pharmaceuticals, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Amneal Pharmaceuticals, Inc. has recorded 157 reports. Market capitalisation: €6.2bn. The latest transaction was disclosed on 25 August 2026 (Don). Among the most active insiders: BOYER ANDREW S. Every trade is accessible without an account.
157
Insider Decl.
n/a
Thresholds
€919,210
3 ops.
Buy Volume
€67m
40 ops.
Sell Volume
40Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,150 of 29,063 companies
41.5
score / 100
Value45
Quality38
FCF yld3.7%
Earn yld1.2%
EV/EBITDA14.5x
ROE·
Gross mgn37%
Net mgn2.4%
Debt/EBITDA4.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 August 2026
Declarations157 total
152,426 shares0Class A Common StockSEC:0001628280-26-058918:0
10,000 shares0Class A Common StockSEC:0001628280-26-057147:1
50,000 shares@ US$17.640.014% mcap47.0% of flowClass A Common StockSEC:0001628280-26-057147:0
210,000 shares@ US$17.400.059% mcap74.0% of flowClass A Common StockSEC:0001628280-26-056754:1
146,403 shares@ US$17.510.042% mcap41.9% of flowClass A Common StockSEC:0001628280-26-056757:0
6,613 shares@ US$17.700.0019% mcap2.4% of flowClass A Common StockSEC:0001628280-26-056754:0
168,573 shares@ US$17.180.047% mcap49.8% of flowClass A Common StockSEC:0001628280-26-056752:0
283,632 sharesClass A Common StockSEC:0001628280-26-056288:0
12,763,469 sharesClass A Common StockSEC:0000898432-26-000655:0
6,381,734 sharesClass A Common StockSEC:0001628280-26-056285:0
6,381,734 sharesClass A Common StockSEC:0001628280-26-056297:0
168,573 shares@ US$17.310.050% mcap100.0% of flowCommonSEC144:0001949846-26-000494
34,819 shares@ US$12.940.0070% mcap72.6% of flowClass A Common StockSEC:0001628280-26-034106:0
59,931 sharesClass A Common StockSEC:0001628280-26-015283:0
59,931 sharesClass A Common StockSEC:0001628280-26-015285:0
22,645 sharesClass A Common StockSEC:0001628280-26-015241:0
45,290 sharesClass A Common StockSEC:0001628280-26-015239:0
39,252 sharesClass A Common StockSEC:0001628280-26-015238:0
36,232 sharesClass A Common StockSEC:0001628280-26-015235:0
50,000 shares@ US$11.72100.0% of flowClass A Common StockSEC:0001628280-25-053188:0
36,331 shares@ US$2.752.8% of flowClass A Common StockSEC:0001628280-25-052413:0
32,000 shares@ US$9.2329.4% of flowClass A Common StockSEC:0001781149-25-000006:0
114,492 shares@ US$9.6631.9% of flowClass A Common StockSEC:0001738061-25-000004:0
175,000 shares@ US$2.7520.4% of flowClass A Common StockSEC:0001628280-25-041033:0
71,694 shares@ US$9.2928.1% of flowClass A Common StockSEC:0001723128-25-000052:0
25 of 157 declarations
关于 Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc.（纳斯达克股票代码：AMRX）是一家在美国纳斯达克市场上市的美国生物制药公司，总部位于美国新泽西州布里奇沃特。该公司由Chirag和Chintu Patel兄弟于2002年创立，其明确的使命是：通过以可负担的价格提供高质量的治疗方案，改善人们获得基本药物的途径。随着时间的推移，Amneal 已从一家专注于仿制药的企业发展成为一个多元化的制药平台，涵盖可负担药物、专科药物和分销服务。（[investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Unveils-Bold-New-Brand-to-Reimagine-Whats-Possible-in-Making-Medicine-Accessible-for-All-2026-PkNbhmgDo5/default.aspx?utm_source=openai)） 如今，Amneal 报告了三个业务部门：可负担药物、专科药物和AvKARE。可负担药物包括零售仿制药、无菌注射剂、生物仿制药和某些国际收入。该部门涵盖了广泛的剂型和给药系统组合，包括比商品化仿制药面临更高技术和监管壁垒的更复杂产品。专科药物部门主要集中于中枢神经系统和内分泌疾病。AvKARE 主要向美国政府机构和机构客户提供药品、医疗和外科产品及服务。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000012/R35.htm?utm_source=openai)） 从竞争角度来看，Amneal 的差异化在于其能够参与制药价值链的多个环节。它在高销量仿制药领域竞争，但在技术要求更高的注射剂、生物仿制药和品牌专科疗法领域也有所涉足。该公司还强调其在美国拥有相当规模的制造和研发基地，这支持了供应链弹性、国内生产能力和监管执行。公司近期资料将Amneal 描述为美国仿制药市场处方量领先的公司之一，突显了其在可负担药物方面的规模。（[amneal.com](https://amneal.com/making-medicines-more-accessible-right-here-in-america/?utm_source=openai)） 关键产品对投资案例变得越来越重要。CREXONT 是一种用于帕金森病的缓释卡比多巴/左旋多巴产品，于2024年获得FDA批准并于同年开始商业化，增强了Amneal 的专科药物特许经营权。2025年，该公司还获得了Brekiya 的FDA批准，该产品被描述为首个也是唯一一个用于伴有或不伴有先兆的成人偏头痛和丛集性头痛的即用型二氢麦角胺自动注射器，并于2025年10月商业化推出。这些推出表明其产品组合正逐步向更具差异化、更高价值的产品转变。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1723128/000172312824000032/amrx-20240630.htm?utm_source=openai)） 最近的发展是积极的。Amneal 表示，在2025年初发布的2024年业绩中，所有三个部门的收入均实现了两位数增长；Brekiya 于2025年5月获得FDA批准；该公司于2025年7月宣布对其现有信贷协议进行再融资；它于2025年12月报告了CREXONT 的积极中期4期数据；并于2026年1月公布了全新的品牌形象，以反映其向多元化全球生物制药领导者的转型。（[investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results/default.aspx?utm_source=openai)）
